MONT-SAINT-GUIBERT, Belgique–(BUSINESS WIRE)–Regulatory News:
Celyad SA (Paris:CYAD) (Brussels:CYAD) (anciennement « Cardio3
BioSciences », code Euronext Bruxelles et Paris : CYAD), a
annoncé aujourd’hui son intention de proposer et vendre, selon le marché
et d’autres conditions, approximativement 100 millions USD de ses
actions ordinaires dans une offre globale comprenant une offre d’actions
ordinaires sous la forme d’ADS (American Depositary Shares) aux
États-Unis et une offre d’actions ordinaires en Europe et dans des pays
autres que les États-Unis et le Canada lors d’un placement privé
concomitant (« l’offre globale »). Seuls les investisseurs autorisés en
vertu de la législation applicable pourront participer à ce placement
privé d’actions ordinaires.
Dans le cadre de l’offre globale, Celyad entend accorder aux
souscripteurs une option de trente jours pour l’achat d’actions
ordinaires supplémentaires sous la forme d’ADS liés à l’offre ADS et une
option de trente jours pour l’action d’actions ordinaires
supplémentaires dans le cadre du placement privé d’actions ordinaires,
jusqu’à 15 % des actions ordinaires et des ADS placés dans l’offre
globale.
Les clôtures de l’offre ADS et du placement privé d’actions ordinaires
survenant dans le cadre de l’offre globale seront conditionnées l’une à
l’autre.
Le prix final des actions ordinaires et des ADS placés dans l’offre
globale sera déterminé après la constitution du carnet d’ordre.
Chacun des ADS proposés dans l’offre ADS représente le droit de recevoir
une action ordinaire.
Les actions ordinaires de Celyad sont actuellement cotées sur Euronext
Paris et Euronext Bruxelles, sous le symbole « CYAD ». Une demande a été
formulée pour coter les ADS proposés dans le cadre de l’offre globale au
NASDAQ aux États-Unis, sous le symbole « CYAD ». Une demande sera
formulée pour permettre l’admission des actions ordinaires émises à la
suite de l’offre globale à la cotation sur Euronext Paris et Euronext
Bruxelles.
UBS Investment Bank et Piper Jaffray & Co. agissent comme co-teneurs de
livre et Petercam SA, Bryan, Garnier & Co., LifeSci Capital LLC et Lake
Street Capital Markets LLC agissent comme co-chefs de file pour l’offre
globale proposée.
Un document d’enregistrement relatif aux titres mentionnés dans le
présent document a été déposé auprès de la Securities and Exchange
Commission (SEC) aux États-Unis, mais n’a pas encore pris effet. Les
titres ne peuvent être vendus et aucune offre d’achat ne peut être
acceptée avant l’entrée en vigueur du document d’enregistrement.
Les valeurs mobilières mentionnées dans le présent communiqué de presse
ne pourront être commercialisées qu’au moyen d’un prospectus, dont une
version préliminaire, lorsqu’elle sera disponible, pourra être obtenue
auprès de UBS Securities LLC, Attention: Prospectus Department, 1285
Avenue of the Americas, New York, NY 10019, ou par téléphone au (888)
827-7275, et auprès de Piper Jaffray & Co. Attention: Prospectus
Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, par
téléphone au (800) 747-3924 ou par courriel en écrivant à prospectus@pjc.com.
Ce communiqué de presse ne constitue pas une offre de vente ni la
sollicitation d’achat des titres mentionnés et aucune vente desdits
titres n’interviendra dans un État ou une juridiction où une telle
offre, sollicitation ou vente serait illégale avant que les titres ne
soient enregistrés ou que leur placement ne soit autorisé en vertu des
lois sur les valeurs mobilières de l’État ou de la juridiction en
question.
***END***
To subscribe to Celyad’s newsletter, visit www.celyad.com
Follow
us on Twitter @CelyadSA
About Celyad
Founded in 2007, and based in Belgium, Celyad is a leader in engineered
cell therapy treatments with clinical programs initially targeting
indications in cardiology and oncology. Celyad is developing its lead
cardiovascular disease product candidate, C-Cure®, for the treatment of
ischemic heart failure, and has completed enrolment of a Phase III trial
in Europe and Israel. In addition, the Company is developing a novel
portfolio of CAR T-cell therapies that utilize human Natural Killer cell
receptors for the treatment of numerous blood and solid cancers. Its
lead oncology product candidate, NKG2D CAR T-cell, entered a Phase I
clinical trial in April 2015.
Celyad’s shares are listed on Euronext Brussels and Euronext Paris under
the ticker symbol CYAD.
To learn more about Celyad, please visit www.celyad.com
Forward looking statements
In addition to historical facts or statements of current condition, this
press release contains forward-looking statements, which reflect our
current expectations and projections about future events, and involve
certain known and unknown risks, uncertainties and assumptions that
could cause actual results or events to differ materially from those
expressed or implied by the forward-looking statements. These risks,
uncertainties and assumptions could adversely affect the outcome and
financial effects of the plans and events described herein. These
forward-looking statements are further qualified by important factors,
which could cause actual results to differ materially from those in the
forward-looking statements, including timely submission and approval of
anticipated regulatory filings; the successful initiation and completion
of clinical trials, including Phase III clinical trials for C-Cure® and
Phase I clinical trial for NKG2D CAR T-cell additional clinical results
validating the use of adult autologous stem cells to treat heart failure
and CAR T-cell autologous therapy to treat cancer; satisfaction of
regulatory and other requirements; actions of regulatory bodies and
other governmental authorities; obtaining, maintaining and protecting
intellectual property, our ability to enforce our patents against
infringers and defend our patent portfolio against challenges from third
parties, competition from others developing products for similar uses,
our ability to manage operating expenses, and our ability to obtain
additional funding to support our business activities and establish and
maintain strategic business alliances and business initiatives. Any
forward-looking statements represent our views only as of today and
should not be relied upon as representing our views as of any subsequent
date. We explicitly disclaim any obligation to update any
forward-looking statements.
C3BS-CQR-1, C-Cure, NKG2D CAR T-cell, C-Cathez, OnCyte,
Celyad, Cardio3 BioSciences and the Cardio3 BioSciences, Celyad, C-Cathez,
CHART-1, CHART-2 and OnCyte logos are signs internationally protected
under applicable Intellectual Property Laws. Mayo Clinic holds equity in
Celyad as a result of intellectual property licensed to the Company.
Important information
This press release is not an offer to sell nor a solicitation to buy the
new shares nor a prospectus for the purposes of Directive 2003/71/EC
(such Directive, together with any applicable implementing measures in
the relevant member state of the European Economic Area and as amended,
including by Directive 2010/73/EU, to the extent implemented in the
relevant member state, the “Prospectus Directive”). There will be no
offer to the public of the new shares in any member state of the
European Economic Area and no prospectus or other offering document has
been or will be prepared in connection with the sale of the new shares
by the Company in the European Economic Area. In the European Economic
Area the new shares will only be offered and sold to “qualified
investors” as defined in the Prospectus Directive or in other
circumstances falling within Article 3(2) of the Prospectus Directive.
This press release does not constitute an offer of the new shares to the
public in the United Kingdom, nor is it intended to be an inducement to
engage in investment activity for the purpose of section 21 of the
Financial Services and Markets Act 2000 (as amended) of the United
Kingdom. Consequently, this press release is only directed at (i)
persons who are outside the United Kingdom; (ii) investment
professionals within Article 19(5) of the Financial Services and Markets
Act 2000 (Financial Promotions) Order 2005 as amended (the “Order”);
(iii) persons falling within Article 49(2)(a)-(d) of the Order; or (iv)
other persons to whom it may be lawfully be communicated, together being
referred to as “relevant persons”. The new shares are only available to,
and any invitation, offer or agreement to purchase or otherwise acquire
the new shares will be engaged in only with relevant persons. Any person
who is not a relevant person should not act or rely on this document or
any of its contents.
Contacts
For more information, please contact:
For Europe :
Consilium Strategic Communications
Amber Bielecka, Chris
Welsh, and Laura Thornton
T: +44 (0)20 3709 5700
celyad@consilium-comms.com
ou
For
the U.S. : The Ruth Group
Lee Roth (Investors), and Kirsten
Thomas (Media)
T: +1 646 536 7012 / 7014
celyad@theruthgroup.com
ou
For
France : NewCap
Pierre Laurent and Nicolas Mérigeau
T:
+ 33(0)1 44 71 94 94
celyad@newcap.fr
ou
Celyad
Christian
Homsy, CEO and Patrick Jeanmart, CFO
T: +32 (0)10 39 41
00
pjeanmart@celyad.com